RESUMO
BACKGROUND: The surgical treatment of pleural empyema should be carried out depending on the stage of the disease and the patient's symptoms. The aim of this study was to evaluate the outcomes of surgical pleural empyema treatment. PATIENTS AND METHODS: Retrospective analysis of all patients with pleural empyema treated surgically between January 2008 and December 2013. The primary endpoint of the study was inpatient lethality. Secondary endpoints included duration of inpatient stay, type of treatment (surgical/conservative), proof of pathogen and type, alteration and duration of antibiotic therapy. RESULTS: Of 359 patients, 0.8â% (n = 3) had stage I empyema, 50.4â% (n = 181) had stage II and 48.7â% (n = 175) had stage III. The most frequent causes (32.4â%) included acute pneumonia (parapneumonic pleural empyema), surgery (usually thoracic) in 18.0â% of cases and previous pneumonia (postpneumonic pleural empyema) in 15.4â%. Surgery was performed in 86â% of cases (operative procedures: open thoracotomy 85â%, VATS 15â%). The average duration of inpatient stay was 20 days for stages II and III. Recovery following VATS was significantly shorter in stage II compared to thoracotomy (p = 0.022). Hospital lethality amounted to 7.0â% (25 patients). The lethality rate was 5.5â% (10/185) in stage II and 8.6â% (15/175) in stage III. Patients with confirmed pathogens had a significantly worse mortality rate across all stages (9.8â%) than patients with no confirmed pathogens (4.0â%, p = 0.034). Age, malignant underlying disease, multiple comorbidities, immunosuppression, a change in antibiotic regimens and sepsis were significant risk factors. CONCLUSION: The inpatient lethality of patients with pleural empyema correlates with the stage of the condition. Positive confirmation of pathogens, sepsis, a higher age, multiple comorbidities, malignant tumour disease, immunosuppression and a change of antibiotics are negative prognostic factors.